RevitalVision
Neurological Treatment for Vision Disorders
Company Overview
Snapshot
Founded in December 2019 by Yair (Gottlieb) Yahav, RevitalVision operates with 11–50 employees. The company has raised $3.7M across three funding rounds. In January 2026, RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile Nystagmus.
Business overview
RevitalVision is a SaaS-based digital health startup focused on vision improvement within the ophthalmic market. The company develops non-invasive technology that neurologically enhances eyesight, addressing the needs of individuals whose vision impairments are not met by traditional treatments. Its core technology utilizes brain science and proprietary algorithms, clinically validated for various eye diseases and vision impairments, including amblyopia. RevitalVision serves eye care specialists, offering tools to improve patient vision beyond optical correction, and eye surgery clinics by helping reduce post-surgery visits for patients with neuro-adaptation challenges or side effects like reduced contrast sensitivity.
Strategic signal
In January 2026, RevitalVision published positive clinical data for its digital therapeutic treatment for infantile Nystagmus. This development is significant as it validates the efficacy and safety of their technology for a specific, challenging vision disorder, potentially expanding the company's addressable market and reinforcing its position as an innovator in neurological vision treatment. For investors, this signals strong clinical progress and potential for broader adoption and reimbursement.
Company Intelligence Q&A
- What is RevitalVision's primary focus?
- RevitalVision is a digital health startup specializing in neurological treatments for vision disorders, utilizing SaaS-based technology to enhance eyesight.
- When was RevitalVision founded?
- RevitalVision was founded in December 2019.
- What significant clinical milestone did RevitalVision achieve?
- In January 2026, RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile Nystagmus.
- How much capital has RevitalVision raised?
- RevitalVision has raised a total of $3.7M across three funding rounds.
- What is RevitalVision's employee count?
- RevitalVision operates with 11–50 employees.